플러스100%마이너스

  • 화면크기
통합검색

한의약융합데이터센터


근거중심한의약 DB

Home > 한의약융합데이터센터 > 근거중심한의약 DB
Title

Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy.

Authors

Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Friedenreich CM, Yasui Y, Reid RD, Vallerand JR, Adams SC, Proulx C, Dolan LB, Wooding E, Segal RJ.

Journal

Br J Cancer.

Year

2014

Vol (Issue)

111(9)

Page

1718-25.

doi

10.1038/bjc.2014.466.

PMID

25144625

Url

http://www.ncbi.nlm.nih.gov/pubmed/25144625

MeSH

Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
Breast Neoplasms/drug therapy*
Breast Neoplasms/rehabilitation*
Chemotherapy, Adjuvant
Exercise Therapy/classification
Exercise Therapy/methods*
Female
Follow-Up Studies
Humans
Middle Aged
Motor Activity
Patient Compliance
Prognosis
Quality of Life*

Keywords

한글 키워드

KMCRIC
Summary & Commentary

KMCRIC 비평 보기 +

Korean Study

Abstract

Background:The Combined Aerobic and Resistance Exercise Trial tested different types and doses of exercise in breast cancer patients receiving chemotherapy. Here, we explore potential moderators of the exercise training responses.Methods:Breast cancer patients initiating chemotherapy (N=301) were randomly assigned to three times a week, supervised exercise of a standard dose of 25-30 min of aerobic exercise, a higher dose of 50-60 min of aerobic exercise, or a higher dose of 50-60 min of combined aerobic and resistance exercise. Outcomes were patient-reported symptoms and health-related fitness. Moderators were baseline demographic, exercise/fitness, and cancer variables.Results:Body mass index moderated the effects of the exercise interventions on bodily pain (P for interaction=0.038), endocrine symptoms (P for interaction=0.029), taxane/neuropathy symptoms (P for interaction=0.013), aerobic fitness (P for interaction=0.041), muscular strength (P for interaction=0.007), and fat mass (P for interaction=0.005). In general, healthy weight patients responded better to the higher-dose exercise interventions than overweight/obese patients. Menopausal status, age, and baseline fitness moderated the effects on patient-reported symptoms. Premenopausal, younger, and fitter patients achieved greater benefits from the higher-dose exercise interventions.Conclusions:Healthy weight, fitter, and premenopausal/younger breast cancer patients receiving chemotherapy are more likely to benefit from higher-dose exercise interventions.British Journal of Cancer advance online publication, 21 August 2014; doi:10.1038/bjc.2014.466 www.bjcancer.com.

국문초록

Language

영어

첨부파일